Flexion Therapeutics, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year ended December 31, 2019. The company’s unaudited revenue for the fourth-quarter of 2019 is estimated to be $23.7 million. The company’s total revenue for the full-year 2019 is estimated to be $73 million. For the year 2020, the company expects 2020 ZILRETTA®product revenue to be in the range of $120 million to $135 million.